Relevance to NICE guidance programmes
Zonisamide as adjunctive therapy for treating partial seizures, with or without secondary generalisation, in children and young people aged 6 years and over was not considered appropriate for a NICE technology appraisal.
NICE published an evidence summary on zonisamide monotherapy for treating partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy in April 2013 (ESNM17).
Zonisamide as adjunctive therapy for partial (focal) seizures in epilepsy was considered during the development of The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (NICE clinical guideline 137). Based on evidence that was available at the time (up to June 2010), the Guideline Development Group found that zonisamide was one of several anti-epileptic drugs that were more costly and less effective than other cost-effective treatment alternatives. The Guideline Development Group concluded that eslicarbazepine acetate, lacosamide, pregabalin, tiagabine and zonisamide should be considered only when initial adjunctive therapy options are contraindicated, ineffective or not tolerated.